Indivior signs deal to sell schizophrenia drug in Canada

03:20 EDT 9 May 2019 | Reuters

British drugmaker Indivior Plc on Thursday signed a licensing agreement with HLS Therapeutics Inc for the sale of its schizophrenia drug Perseris in Canada.

Original Article: Indivior signs deal to sell schizophrenia drug in Canada


More From BioPortfolio on "Indivior signs deal to sell schizophrenia drug in Canada"

Quick Search


Relevant Topics

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Schizophrenia is a common  serious long-term mental health condition that affects 5 in 1000 in the UK. It causes a range of different psychological symptoms; hallucinations, delusions, muddled thoughts based on the hallucinations or delusions and ch...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...